Clinical Trials Logo

Filter by:
NCT ID: NCT03626441 Completed - Clinical trials for Postoperative Nausea and Vomiting

The Effect of Ginger on the Incidence of Postoperative Nausea and Vomiting

Start date: December 2, 2017
Phase: Phase 2
Study type: Interventional

This study evaluates the effectiveness of ginger on the incidence of postoperative nausea and vomiting in patients undergoing gynaecological surgery. Half the patients were given an oral dose of ginger preoperatively and half received placebo.

NCT ID: NCT03488264 Completed - Quality of Life Clinical Trials

Stigma, Self-management, & Quality of Life in SCD

SSQ
Start date: February 13, 2018
Phase:
Study type: Observational

Many individuals with sickle cell disease experience both a poor quality of life and stigma. Individuals with SCD often experience high levels of stigma which can be a barrier to good self-management and hinder quality of life. The purpose of this research is to improve understanding of the relationships between stigma, self-management, and quality of life in SCD in the United States and Jamaica. The findings from this project will contribute to the development of a tool to measure self-management strategies and will also guide the development of interventions to improve SCD self-management.

NCT ID: NCT03478982 Completed - Epilepsy Clinical Trials

Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern

StATES
Start date: March 16, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, double-blind, randomized, parallel group, dose-ranging study to investigate the efficacy and clinical usability of STAP-001 in adult (18 years of age and older) subjects with epilepsy with a predictable seizure pattern. These subjects have an established diagnosis of focal or generalized epilepsy with a documented history of predictable seizure episodes. This is an in-patient study. The subjects will be admitted to a Clinical Research Unit (CRU) or Epilepsy Monitoring Unit (EMU) for study participation. The duration of the stay in the in-patient unit will be 2-8 days. One seizure event per subject will be treated with study medication. The duration and timing of the seizure event and occurrence of subsequent seizures will be assessed by the Staff Caregiver(s)1 through clinical observation and confirmed with video electroencephalogram (EEG).

NCT ID: NCT03449940 Completed - Clinical trials for Erectile Dysfunction

Penile Fracture: A Comparison of Erectile Function After Immediate Repair Versus Delayed Repair

Start date: January 2015
Phase: N/A
Study type: Interventional

To prospectively compare erectile function at 12 months, utilizing the abbreviated International Index of Erectile Function-5 (IIEF-5) score, for men treated with an immediate repair versus a delayed repair.

NCT ID: NCT03269110 Enrolling by invitation - Asthma Clinical Trials

Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)

Start date: July 1, 2017
Phase:
Study type: Observational

FACT 4 Child is a follow up study of mothers who participated in the Folic Acid Clinical Trial (NCT01355159) and their children at 4-6 years of age to determine the effect of high dose folic acid supplementation on social impairments associated with Autism Spectrum Disorders (ASDs), and deficiencies in a range of executive function and emotional and behavioural problems in young children, and the risk of death.

NCT ID: NCT03151629 Recruiting - Prostate Cancer Clinical Trials

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

IRONMAN
Start date: July 21, 2017
Phase:
Study type: Observational [Patient Registry]

Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.

NCT ID: NCT03036813 Completed - Sickle Cell Disease Clinical Trials

Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)

GBT_HOPE
Start date: December 2016
Phase: Phase 3
Study type: Interventional

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease

NCT ID: NCT02802800 Completed - Fitness Training Clinical Trials

A Comparison of Land and Water Based Plyometric Training on Fitness of Field Hockey Players

Start date: June 2016
Phase: N/A
Study type: Interventional

Field hockey players, recruited from clubs in Jamaica, will be randomized to either a water training or land training groups. Persons will be exposed to 6 weeks of plyometric training with two sessions per week. Pre and post test measures will be done for lower limb power, flexibility and agility. Distance covered, pace, heart rates and exertion during a match will also be assessed.

NCT ID: NCT02556099 Active, not recruiting - Sickle Cell Anemia Clinical Trials

EXTEND EXpanding Treatment for Existing Neurological Disease

Start date: August 2014
Phase: Phase 2
Study type: Interventional

The primary goal of the Phase II EXTEND trial is to investigate the effects of open-label hydroxyurea treatment, escalated to maximum tolerated dose, for children with Sickle Cell Anemia and either conditional (170 - 199 cm/sec) or abnormal (≥200 cm/sec) Transcranial Doppler velocities. The primary endpoint will be measured after 18 months of hydroxyurea but treatment will continue until a common study termination date.

NCT ID: NCT02515838 Completed - Sickle-Cell Disease Clinical Trials

Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD

Start date: July 2015
Phase: Phase 2
Study type: Interventional

A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects with Sickle-Cell Disease (SCD).